Standard BioTools Inc. (LAB)

Standard BioTools Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	106.34	97.95	130.58	138.14	117.24
Revenue Growth (YoY)	8.57%	-24.99%	-5.47%	17.83%	3.79%
Cost of Revenue	55.89	60.9	61.21	54.82	52.96
Gross Profit	50.45	37.05	69.37	83.33	64.28
Selling, General & Admin	87.54	102.29	98.89	97.9	84.48
Research & Development	25.95	37.38	37.94	36.46	31.64
Other Operating Expenses	13.56	13.59	0	0	0
Operating Expenses	127.05	153.26	136.83	134.36	116.12
Operating Income	-76.6	-116.21	-67.46	-51.04	-51.84
Interest Expense / Income	4.57	4.33	3.82	3.57	4.28
Other Expense / Income	-6.96	72.39	-7.62	-0.51	10.59
Pretax Income	-74.2	-192.93	-63.66	-54.1	-66.71
Income Tax	0.45	-2.83	-4.42	-1.08	-1.92
Net Income	-74.66	-190.1	-59.24	-53.02	-64.79
Shares Outstanding (Basic)	79	78	76	72	67
Shares Outstanding (Diluted)	79	78	76	72	67
Shares Change	1.09%	3.32%	5.19%	7.88%	68.41%
EPS (Basic)	-0.94	-2.43	-0.78	-0.74	-0.97
EPS (Diluted)	-0.94	-2.43	-0.78	-0.74	-0.97
Free Cash Flow	-46.12	-93.2	-57.33	-28.13	-37.74
Free Cash Flow Per Share	-0.58	-1.19	-0.76	-0.39	-0.56
Gross Margin	47.44%	37.83%	53.13%	60.32%	54.83%
Operating Margin	-72.03%	-118.64%	-51.66%	-36.94%	-44.22%
Profit Margin	-70.21%	-194.08%	-45.36%	-38.38%	-55.26%
Free Cash Flow Margin	-43.37%	-95.15%	-43.90%	-20.37%	-32.19%
EBITDA	-65.66	-185.1	-56.18	-44.5	-58.34
EBITDA Margin	-61.74%	-188.98%	-43.03%	-32.21%	-49.76%
Depreciation & Amortization	3.98	3.5	3.65	6.03	4.09
EBIT	-69.64	-188.6	-59.84	-50.53	-62.43
EBIT Margin	-65.49%	-192.55%	-45.82%	-36.58%	-53.24%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).